Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
0.184 ^USD	+1.66%		+40.35%	+8.49%

04-03	Sector Update: Health Care Stocks Softer Late Afternoon	MT
04-03	Sector Update: Health Care	MT

Delmar Pharmaceuticals, Inc. Announces the Resignation of Jeffrey Bacha as a President and Chief Operating Officer, Effective January 1, 2018

December 22, 2017 at 10:24 pm

DelMar Pharmaceuticals, Inc. announced that it has entered into a Settlement Agreement with Jeffrey Bacha pursuant to which, effective January 1, 2018, Mr. Bacha will no longer serve as the company's President and Chief Operating Officer.

Latest news about Kintara Therapeutics, Inc.

Sector Update: Health Care Stocks Softer Late Afternoon	04-03	MT
Sector Update: Health Care	04-03	MT
Top Midday Gainers	04-03	MT
Transcript : Kintara Therapeutics, Inc., TuHURA Biosciences, Inc. - M&A Call	04-03
TuHURA Biosciences, Inc. entered into a definitive agreement to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.	04-02	CI
TuHURA Biosciences, Inc. agreed to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.	04-02	CI
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab	03-27	CI
Kintara Therapeutics Continues to Evaluate Strategic Options	02-15	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-14	CI
Kintara Therapeutics, Inc. Announces Initiation of Rem-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer	02-12	CI
Wall Street Set for Cautious Opening in Final Trading Day of a Bullish 2023	12-29	MT
Index Futures Edge Higher to End Mostly Positive Year on High Note	12-29	MT
Top Premarket Gainers	12-29	MT
Kintara Therapeutics Initiates Strategic Review to Optimize Shareholder Value	12-07	MT
Kintara Therapeutics Initiates Review of Strategic Alternatives	12-06	CI
Kintara Therapeutics, Inc. Announces Executive Changes	11-21	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-13	CI
Health Care Up Slightly Amid Mixed Earnings -- Health Care Roundup	31/10/23	DJ
Sector Update: Health Care Stocks Rise Late Afternoon	31/10/23	MT
Sector Update: Health Care	31/10/23	MT
Top MIdday Decliners	31/10/23	MT
Kintara Therapeutics Announces Preliminary Topline Results from GBM AGile Study	31/10/23	CI
Kintara Therapeutics, Inc. Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting	25/09/23	CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	18/09/23	CI
Transcript : Kintara Therapeutics, Inc. - Special Call	21/08/23

Chart Kintara Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.

Sector

Biotechnology & Medical Research

Calendar

22/09/2024 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
KINTARA THERAPEUTICS, INC.	+8.49%	10.01M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	114B
REGENERON PHARMACEUTICALS, INC.	+12.01%	107B
BIONTECH SE	-3.07%	22.22B
ARGENX SE	-0.67%	21.28B
GENMAB A/S	-4.64%	18.8B
BEIGENE, LTD.	-6.90%	17.51B
WUXI APPTEC CO., LTD.	-39.36%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.2B

Bio Therapeutic Drugs

Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Biotechnology & Medical Research

Delmar Pharmaceuticals, Inc. Announces the Resignation of Jeffrey Bacha as a President and Chief Operating Officer, Effective January 1, 2018

Latest news about Kintara Therapeutics, Inc.

Chart Kintara Therapeutics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs